Shots: Regeneron will be responsible to deliver treatment doses for six years post-approval of product from the FDA, will receive compensation of ~$10M & average of $67M/year in 2021 and each for the next five years (2022-2026) respectively In 2019, the PALM trial evaluated REGN-EB3 vs ZMapp conducted in the Democratic Republic of the Congo, […]Read More
Shots: AbCellera to receive upfront, pre-clinical, clinical & commercial milestones including research payments for the non-COVID-19 targets plus royalties on future sales. Eli Lilly to get rights to develop and commercialize the Abs developed in the collaboration In early 2020, the companies collaborated for multi target agreement focusing to develop Abs for COVID-19 while Eli […]Read More
Shots: The companies allied to support Takeda’s research stage gene therapy discovery programs across its core therapeutic areas i.e. oncology, rare diseases, neuroscience and gastroenterology The collaboration leverages s Evotec’s gene therapy capabilities along with its drug discovery platform to support Takeda’s programs The partnership will facilitate Takeda’s delivery of transformative therapies for patients, especially […]Read More
Shots: The companies signed a multi-year, multifaceted collaboration to develop novel Ab to treat & prevent various diseases including oncology and immunology The collaboration leverages H2L2 Harbour Mice platform to generate mAb against SARS CoV 2 – COVID-19 and allow HBM to access Mount Sinai’s research-driven from its clinical practices The collaboration demonstrated HBM’s dedication […]Read More
Shots: Veracyte collaborates with Acerta Pharma, a hematology research and development of AstraZeneca for providing genomic information for supporting development of oncology therapeutics On Dec 03, 2019 the company reported acquisition of its diagnostics rights to the NanoString nCounter platform and genomic tests for breast cancer and lymphoma The focus of the agreement is to […]Read More
Shots: Beacon will take care of drug discovery activities while Arena will focus on development and commercialization of products for multiple immune and inflammatory diseases The focus of the agreement is to develop therapies for G protein-coupled receptor (GPCR) targets and further expanding the footprints in autoimmune diseases Arena has a pipeline of three candidates […]Read More
Shots: The companies collaborated to establish a Virtual Research and Development Center, enabling data sharing and analysis and focusing on research of therapies for multiple types of cancers, including gastrointestinal and lung cancers The focus of the agreement is to combine novel therapies from Boehringer’s oncology pipeline with patient-driven drug-development capabilities of MD Anderson’s Therapeutics […]Read More
Shots: Cancer Research and LifeArc to receive upfront, milestones and royalties on sales of products. Ono to get an option to license the developed product with exclusive WW commercialization rights and will take care of its clinical development for identifying new therapeutic targets & target validation LifeArc will utilize its antibody screening and development expertise […]Read More
Shots: The companies collaborated to develop and commercialize novel in vivo delivery of CRISPR/Cas9 using ProBioGen’s technology. CRISPR Therapeutics also holds an option to license the developed product The focus of the agreement is to expand CRISPR Therapeutics’ in vivo delivery technology in fields of hemoglobinopathies, oncology, regenerative medicine and rare diseases CRISPR Therapeutics’ CRISPR/Cas9 […]Read More
Shots: NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs The focus of the agreement is to develop novel immunotherapies using NextCure’s FIND-IO technology in the fields of oncology FIND-IO platform has ability to identify cell […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
